Drug intelligence / Profile preview

ARO-JNJ2

Development stage: Preclinical
Lead developer: Arrowhead Pharmaceuticals
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

ARO-JNJ2 is an investigational RNA interference (RNAi) therapeutic. It was initially developed by Arrowhead Pharmaceuticals and is now being advanced in collaboration with Johnson & Johnson. The drug is designed to silence specific genes by using small interfering RNA (siRNA) technology, targeting disease-associated gene transcripts[5]. While precise target and disease indication details are not fully disclosed, ARO-JNJ2 is believed to be in preclinical development for oncology applications.

Beyond the preview

Go deeper on ARO-JNJ2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARO-JNJ2.

Explore the full profile